fluconazole has been researched along with methotrexate in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 16 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kano, S; Minato, N; Saito, K; Saito, T; Saku, N; Sato, M; Suzuki, N; Takeda, A | 1 |
| Brôco, N; Sá-Correia, I; Tenreiro, S; Viegas, CA | 1 |
| Fekete-Forgács, K; Kis, B; Lenkey, B; Nagy, G | 1 |
| Brink, NS; Goldstone, AH; Kottaridis, PD; Linch, DC; Mackinnon, S; McKeag, N; Peggs, KS; Preiser, W; Tedder, RS | 1 |
| Gupta, V; Hasnain, SE; Kohli, A; Krishnamurthy, S; Prasad, R | 1 |
| Peckham, SJ; Penmetcha, M; True, DG | 1 |
| Mikamo, H; Ninomiya, M; Tamaya, T | 1 |
| Fujinaga, H; Oda, S; Takahashi, K | 1 |
| Mowad, CM; Sewell, LD; Wilson, ML | 1 |
| Ambudkar, SV; Manoharlal, R; Prasad, R; Prasad, T; Puri, N; Sharma, M; Shukla, S | 1 |
| Billings, SD; Hoschar, AP; McDonnell, JK; Rushing, EC | 1 |
| Byekova, Y; Elewski, B; Hughey, L | 1 |
| Fang, Y; Gao, L; Jia, L; Kosgey, JC; Xiong, J; Yang, J; Yu, P; Zhang, F | 1 |
3 review(s) available for fluconazole and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[A case report--pulmonary cryptococcosis associated with systemic lupus erythematosus and review of 44 cases in Japan].
Topics: Arthritis, Rheumatoid; Cryptococcosis; Drug Therapy, Combination; Female; Fluconazole; Flucytosine; Humans; Japan; Lung Diseases, Fungal; Lupus Erythematosus, Systemic; Methotrexate; Middle Aged; Opportunistic Infections | 1993 |
Systemic drugs in patients with skin diseases.
Topics: Cyclosporine; Fluconazole; Glucocorticoids; Humans; Immunologic Factors; Immunosuppression Therapy; Itraconazole; Methotrexate; Mycophenolic Acid; Naphthalenes; Retinoids; Skin Diseases; Terbinafine | 2011 |
27 other study(ies) available for fluconazole and methotrexate
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
FLR1 gene (ORF YBR008c) is required for benomyl and methotrexate resistance in Saccharomyces cerevisiae and its benomyl-induced expression is dependent on pdr3 transcriptional regulator.
Topics: 4-Nitroquinoline-1-oxide; Antifungal Agents; Antimetabolites, Antineoplastic; Benomyl; Carcinogens; Carrier Proteins; Cycloheximide; DNA Primers; DNA-Binding Proteins; DNA, Fungal; Drug Resistance, Microbial; Electrophoresis, Agar Gel; Fluconazole; Fungicides, Industrial; Gene Expression Regulation, Fungal; Membrane Transport Proteins; Methotrexate; Mutagenesis, Insertional; Organic Anion Transporters; Plasmids; Polymerase Chain Reaction; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Transcription Factors | 1999 |
Effect of fluconazole on the growth and adhesion of Candida albicans in the presence of antineoplastic agents.
Topics: Antifungal Agents; Antineoplastic Agents; Candida albicans; Candidiasis, Oral; Cell Adhesion; Drug Interactions; Epithelial Cells; Etoposide; Fluconazole; Humans; Methotrexate; Microbial Sensitivity Tests; Mouth Mucosa | 1999 |
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Fluconazole; Foscarnet; Humans; Leukemia; Lymphoma; Male; Methotrexate; Middle Aged; Polymerase Chain Reaction; Postoperative Period; Prospective Studies; Risk; Survival Rate; Time Factors; Tissue Donors; Transplantation, Homologous | 2000 |
Specificity of drug transport mediated by CaMDR1: a major facilitator of Candida albicans.
Topics: Antifungal Agents; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport; Candida albicans; Cell Line; Cloning, Molecular; Drug Resistance, Multiple, Fungal; Fluconazole; Humans; Methotrexate; Transformation, Genetic | 2001 |
Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.
Topics: Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Cryptococcosis; Cryptococcus neoformans; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Follow-Up Studies; Fungemia; Humans; Immunocompromised Host; Infliximab; Infusions, Intravenous; Male; Methotrexate; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed | 2002 |
Tuboovarian abscess caused by Candida glabrata in a febrile neutropenic patient.
Topics: Abscess; Adult; Amphotericin B; Antifungal Agents; Antimetabolites, Antineoplastic; Candida glabrata; Candidiasis; Diagnosis, Differential; Fallopian Tubes; Female; Fever; Fluconazole; Genital Diseases, Female; Granulocyte Colony-Stimulating Factor; Humans; Hydatidiform Mole; Magnetic Resonance Imaging; Methotrexate; Neutropenia; Pregnancy | 2003 |
Infectious myositis involving the piriformis in a patient with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal; Antifungal Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Candidiasis; Drug Therapy, Combination; Female; Fluconazole; Humans; Infliximab; Methotrexate; Middle Aged; Muscle, Skeletal; Myositis; Organophosphates; Staphylococcal Infections; Tomography, X-Ray Computed | 2006 |
Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; Female; Finger Injuries; Fluconazole; Humans; Hydroxychloroquine; Methotrexate; Middle Aged | 2008 |
Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.
Topics: Anisomycin; Antifungal Agents; Biological Transport; Candida albicans; Curcumin; Cycloheximide; Drug Synergism; Enzyme Inhibitors; Fluconazole; Itraconazole; Ketoconazole; Methotrexate; Miconazole; Multidrug Resistance-Associated Proteins; Pyrimidines; Rhodamines; Saccharomyces cerevisiae; Triazoles; Voriconazole | 2009 |
Iatrogenic oral hairy leukoplakia: report of two cases.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Clobetasol; Dapsone; Dermatologic Agents; Dexamethasone; Diabetes Mellitus, Type 2; Epstein-Barr Virus Infections; Female; Fluconazole; Humans; Immunocompromised Host; Leukoplakia, Hairy; Lichen Planus; Methotrexate; Nystatin; Prednisone; Zinc Oxide | 2011 |
In vitro synergy of azole antifungals and methotrexate against Candida albicans.
Topics: Candida albicans; Cell Membrane; Cell Wall; Dose-Response Relationship, Drug; Drug Synergism; Fluconazole; Gastrula; In Vitro Techniques; Itraconazole; Methotrexate; Microbial Sensitivity Tests; Microscopy, Electron, Transmission; Voriconazole | 2019 |